Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCL201 · 1 trial · 1 indication
Characterized by Frequency, severity and seriousness of AEs, lab abnormalities and other safety parameters such as electrocardiogram (ECG) changes
| Arm | Type | Description |
|---|---|---|
| Follicular lymphoma (FL) | EXPERIMENTAL | - |
| Mantle cell lymphoma (MCL) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BCL201 | DRUG | - |
| Idelalisib | DRUG | - |
Inclusion Criteria: * Histologically confirmed diagnosis of FL or MCL according to WHO 2008 * Relapsed or refractory with at least one (FL) or two (MCL), but not more than four, prior lines of antineoplastic regimens. * Either FDG-avid on FDG-PET or measurable disease by CT on cross sectional imagi...
BCL201 is an investigational small molecule being studied for the treatment of Follicular Lymphoma and Mantle Cell Lymphoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
BCL201 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS.
BCL201 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies and is still being evaluated for safety and efficacy in clinical trials.
BCL201 has been studied in one completed Phase 1 clinical trial, identified as NCT02603445. This trial evaluated the safety and efficacy of BCL201 in combination with idelalisib in patients with Follicular Lymphoma and Mantle Cell Lymphoma.
No, BCL201 is not the same as idelalisib. BCL201 is a separate investigational drug being studied in combination with idelalisib in a clinical trial for Follicular Lymphoma and Mantle Cell Lymphoma.